Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Early Intervention, Educational 5Radiotherapy 4Psychiatric Rehabilitation 4sargramostim 3pembrolizumab 3Trastuzumab 3Methods 3palbociclib 2cediranib 2Standard of Care 2Specimen Handling 2Mental Status and Dementia Tests 2Magnetic Resonance Spectroscopy 2Irinotecan 2Interleukin-12 Subunit p35 2Interferon-alpha 2Fluorouracil 2Fluorodeoxyglucose F18 2Erlotinib Hydrochloride 2Docetaxel 2Counseling 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1sapanisertib 1relatlimab 1pertuzumab 1osimertinib 1orantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Dalteparin × Genitourinary × Clear all
NCT00003674 2016-07-13

Standard Therapy With or Without Dalteparin in Treating Patients With Advanced Breast, Lung, Colorectal, or Prostate Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Completed
141 enrolled
BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡